Edition:
United States

Proteon Therapeutics Inc (PRTO.OQ)

PRTO.OQ on NASDAQ Stock Exchange Global Market

2.35USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$2.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,361
52-wk High
$2.85
52-wk Low
$1.15

Chart for

About

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $41.54
Shares Outstanding(Mil.): 17.67
Dividend: --
Yield (%): --

Financials

  PRTO.OQ Industry Sector
P/E (TTM): -- 199.23 33.71
EPS (TTM): -2.12 -- --
ROI: -81.89 -0.66 13.09
ROE: -142.13 -2.84 14.92

BRIEF-Proteon Says Has Sufficient Capital For Operations Into Q4 Of 2019

* PROTEON THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Mar 14 2018

BRIEF-Proteon Therapeutics Completes Enrollment In Patency-2, Phase 3 Clinical Trial Of Investigational Vonapanitase

* PROTEON THERAPEUTICS COMPLETES ENROLLMENT IN PATENCY-2, PHASE 3 CLINICAL TRIAL OF INVESTIGATIONAL VONAPANITASE Source text for Eikon: Further company coverage:

Mar 05 2018

BRIEF-Proteon Therapeutics Q3 ‍loss per share $1.08​

* Proteon Therapeutics announces third quarter 2017 financial results

Nov 07 2017

Earnings vs. Estimates